- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02337959
Clinical Evaluation of DRX Plus 3543 and DRX Plus 3543C Digital Detectors
Study Overview
Detailed Description
The purpose of this clinical study is to evaluate the imaging performance of the DRX Plus 3543 and DRX Plus 3543C Detectors (flat panel digital imaging devices) ("investigational device") as compared to the currently marketed Carestream DRX-1 Detector ("predicate device"). The evaluation will consist primarily of comparing the diagnostic image quality of double-imaged pediatric and adult cadaver studies and adult live human subject studies acquired under the same exposure technique for similar detector types (i.e. comparing DRX-1 GOS predicate with DRX Plus GOS) or exposure adjusted technique when different detector types are compared.
Under the same position and radiological technique, pediatric and adult cadaver studies, and adult live human subject studies, using double-exposed images will be acquired to evaluate the diagnostic image quality of the investigational device versus the predicate device. Target images will be assembled and reviewed in a side-by-side Comparative Evaluation to statistically confirm the findings of this evaluation.
The live human subject portion of this study will be performed on healthy volunteers. Each volunteer will sign an Informed Consent after which they will have two (2) x-rays taken. The first x-ray will follow standard technique using the cleared predicate detector currently in use at the site. Following the first x-ray, we will take one additional x-ray of the same part of the body with one (1) of the investigational detectors. The x-ray from the investigational detector will not be used to diagnose.
If the x-ray obtained by the standard DR x-ray detector shows any unforeseen, unusual or abnormal findings, these findings will be communicated to the subject and their doctor by USPS mail.
Reason for Observational Study Type: There are three (3) physical detectors being used in this study. Each detector is 35 centimeters by 43 centimeters. None of the subjects will given a detector.
All subjects are healthy volunteers recruited by flyer. All subjects will be imaged with the same predicate detector and one (1) of the investigational detectors.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642-8648
- University of Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- X-ray images of nearly identical positioning and exposure
- No visible image artifacts
- Subject 21years or older
- Subject has provided informed consent
- Subject is in good general health
- Subject is able to stand for two (2) x-rays
Exclusion Criteria:
- Images that are not clinically acceptable for clinical radiographic reading as determined by the Principal Investigator.
- Subject is pregnant or suspicious of being pregnant
- Not able or willing to provide Informed Consent, or consent is withdrawn
- Not able to collect all required case information
- Subject has a history of high radiation exposure:
- Has undergone radiation therapy
- Has had two (2) or more CT scans within the past year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Predicate & Invest.-GOS
Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
|
Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector.
Multiple exams (head, chest, legs, etc) were made on the cadavers.
Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
|
Experimental: Predicate & Invest.-CsI
Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
|
Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector.
Multiple exams (head, chest, legs, etc) were made on the cadavers.
Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
|
Experimental: Predicate & Invest.-Cadavers GOS & CsI
Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers.
Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.
|
Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector.
Multiple exams (head, chest, legs, etc) were made on the cadavers.
Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radlex Scale for Diagnostic Capability Ratings
Time Frame: 9 weeks after last x-ray capture
|
1-Non-diagnostic Unacceptable for diagnostic purposes.
Little or no clinically usable diagnostic information (e.g., gross underexposure, system failure or extensive motion artifact).
Almost all such imaging should be repeated.
2-Limited Acceptable, with some technical defect (motion artifact, body habitus/poor x-ray penetration, or patient positioning may limit visualization of some body-regions but still adequate for diagnostic purposes).
Not as much diagnostic information as is typical for an examination of this type, but likely sufficient.
3-Diagnostic Image quality that would be expected routinely when imaging cooperative patients.
4-Exemplary Good, most adequate for diagnostic purposes.
Image quality that can serve as an example that should be emulated.
|
9 weeks after last x-ray capture
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pair Preference Rating
Time Frame: 9 weeks after last x-ray capture
|
During the Reader Study the radiologists completed a paired preference rating using the following scale: -3, Image displayed on left is strongly preferred; -2, Image displayed on left is moderately preferred; -1, Image displayed on left is slightly preferred; 0, No preference between the images; 1, Image displayed on right is slightly preferred; 2, Image displayed on right is moderately preferred; 3, Image displayed on right is strongly preferred.
Both the predicate and investigational images were randomly assigned to appear on the right or left monitors.
A spreadsheet was used for managing the data.
Prior to analysis, raw ratings were converted so that those in favor of the investigational device were made positive, and ratings in favor of the predicate device were made negative.
|
9 weeks after last x-ray capture
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Susan Hobbs, MD, University of Rochester
- Principal Investigator: Steven Don, MD, St. Louis Children's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 6K9740
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Radiation
-
Cancer Institute and Hospital, Chinese Academy...Terminated
-
Massachusetts General HospitalCompletedMesenchymal TumorUnited States
-
Canadian Cancer Trials GroupAlliance for Clinical Trials in Oncology; NRG Oncology; Eastern Cooperative Oncology... and other collaboratorsRecruitingBreast CancerUnited States, Canada
-
Ohio State University Comprehensive Cancer CenterCompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingStage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8United States
-
University of ChicagoRecruitingLymphoma | Hodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
University of Texas Southwestern Medical CenterCompletedNon-small Cell Lung CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedNonsmall Cell Lung Cancer Stage III | Nonsmall Cell Lung Cancer, Stage IIUnited States